MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • MDS Virtual Congress 2021

    Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions

    K. Lyons, R. Pahwa, N. Crouse, L. Llorens, R. Howard, A. Formella (Kansas City, USA)

    Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…
  • MDS Virtual Congress 2021

    Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)

    T. Mishima, SW. Chiu, H. Saiki, T. Yamaguchi, Y. Shimo, T. Maeda, H. Watanabe, K. Kashihara, M. Nomoto, N. Hattori, Y. Tsuboi (Fukuoka, Japan)

    Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…
  • MDS Virtual Congress 2021

    Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease

    C. Tanner, J. Lytle, A. Formella (San Francisco, USA)

    Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…
  • MDS Virtual Congress 2021

    The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, G. Tayupova, S. Umutbaev, A. Baitimerov, R. Magzhanov (Ufa, Russian Federation)

    Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…
  • MDS Virtual Congress 2021

    SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models

    A. Bordbar, K. Merchant, D. Weiner, M. Hill, J. Brotchie, T. Johnston, I. Famili (San Diego, USA)

    Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…
  • MDS Virtual Congress 2021

    Gut dysbiosis in Parkinson’s disease with motor complications

    K. Takahashi, H. Nishiwaki, M. Ito, K. Iwaoka, K. Yamahara, K. Takahashi, Y. Suzuki, K. Taguchi, Y. Tsuboi, K. Kashihara, M. Hirayama, K. Ohno, T. Maeda (Shiwa, Japan)

    Objective: We aimed to identify gut dysbiosis in Parkinson's disease patients with motor complications. Background: Recently, several evidences suggest that the gut microbiota is associated…
  • MDS Virtual Congress 2020

    Gpi Deep Brain Stimulation After Many Years of Subthalamic Nucleus Stimulation: Case Report

    Z. Tufekcioglu, T. Karanci, S. Albayrak (Istanbul, Turkey)

    Objective: Management of motor complications after subthalamic nucleus (STN) deep brain stimulation (DBS) with globus pallidus interna (Gpi) stimulation. Background: Deep brain stimulation is an…
  • MDS Virtual Congress 2020

    The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease: a pilot study

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, A. Baitimerov, G. Tayupova, R. Magzhanov (Ufa, Russian Federation)

    Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…
  • MDS Virtual Congress 2020

    Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials

    R.A Hauser, D. Chernick, A. Formella (Tampa, FL, USA)

    Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…
  • MDS Virtual Congress 2020

    Persistent head dyskinesias following STN DBS in Parkinson’s disease resolve using directionality

    C. vander Linden, C. Bogaert-Miclaus, D. Colle (Ghent, Belgium)

    Objective: To control subthalamic nucleus deep brain stimulation (STN DBS) induced dyskinesias in Parkinson's disease (PD) using directionality. Background: Levodopa-induced dyskinesias (LID) frequently occur in…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Unusual prolonged survival in multiple system atrophy: A case report
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley